Clinical Trial Update: A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) [Phase 2]

View source ↗

Summary

Phase II trial evaluating 18F-AV-45 PET imaging in healthy volunteers, mild cognitive impairment, and Alzheimer's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• AMYVID (Florbetapir F-18)

Snippet

Sponsor: Avid Radiopharmaceuticals | Conditions: Alzheimer's Disease, Mild Cognitive Impairment | Phase 2 | Status: COMPLETED | Results posted: 2012-05-03